REG - Medpal AI PLC - Pharmacy Operational Update

Medpal AIAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260601:nRSA3339Ga&default-theme=true

RNS Number : 3339G  Medpal AI PLC  01 June 2026

1 June 2026

MedPal AI plc

("MedPal AI", "MedPal" or the "Company")

Pharmacy Operational Update

 

Record Monthly Dispensing Volume - Best Month Since Launch

Over 250,000 Prescription Items Dispensed Since Launch

MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-powered, integrated digital health
and pharmacy company, is pleased to provide an operational update on the
continued strong growth in dispensing volumes at its wholly owned pharmacy
operations.

•   Record month: over 42,250 prescription items dispensed in May 2026 -
the Company's best-performing month since pharmacy operations commenced,
surpassing the previous record of 41,000 items, reflecting underlying momentum
in patient demand.

•   Major cumulative milestone: the Company has now dispensed over 250,000
prescription items in total since launch, underscoring the sustained,
accelerating adoption of its NHS and private pharmacy services and the
Company's dispensing platform retains substantial headroom for further growth.

•   Strong margins: as reported in the Company's interim results for the
six months ended 28 February 2026, pharmacy gross margin strengthened to over
34% as dispensing volumes scaled, reflecting the operational leverage of the
Company's automated dispensing model.

•   Annualised run rate: based on the May 2026 dispensing volume the
Company's pharmacy operations are now trading at an annualised turnover run
rate in excess of £5 million.

 

Chief Executive Officer's commentary

Jason Drummond, Founder and Chief Executive Officer of MedPal AI, commented:

"May was our best month yet, with over 42,250 items dispensed, and we have now
passed a quarter of a million prescriptions since we began. To reach this
scale in such a short period is a powerful validation of our automated,
technology-led model - which, as our interim results showed, is delivering
pharmacy gross margins of over 34% as we grow. We have built this momentum
from a standing start, and with significant capacity still available across
our dispensing operations, the Board sees a clear runway for continued,
profitable growth."

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

 

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer                 Via Square1 Consulting

 Cairn Financial Advisers LLP                            +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Oak Securities (a trading name of Merlin Partners LLP)  +44 (0) 20 3973 3678

 Tim Dainton/Calvin Man
 Clear Capital Markets Limited                           +44 (0) 20 3869 6080

 Bob Roberts

 Square1 Consulting                                      +44 (0) 20 7929 5599

 David Bick                                              +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company building the MedPal Health OS -
a vertically integrated, closed-loop platform spanning AI wellness, clinical
services, and automated pharmacy fulfilment. Its core app aggregates data from
over 100 wearable devices and health apps (including Apple Health, Fitbit,
Garmin, and Whoop) into a unified health profile, offering personalised,
non-clinical lifestyle guidance through its AI wellness coach and acting as
the consumer front door to the Company's clinical and pharmacy services.

 

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages BD Rowa VMAX
robotic dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

 

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms. The Company's LEI is
984500EDP8B0A14CBA61.

 

Forward Looking Statements

This announcement contains forward-looking statements, which are based on the
Company's current expectations, intentions and projections regarding its
future performance, anticipated events or trends and other matters that are
not historical facts. Forward-looking statements are often identified by words
such as "believes", "expects", "intends", "may", "will", "should", "could",
"plans", "targets", "aims" or similar expressions. Such statements are subject
to risks, assumptions and uncertainties and actual results, performance or
events may differ materially from those expressed or implied by them. The
Company undertakes no obligation to update any forward-looking statements,
except as required by applicable law, the AIM Rules for Companies, the UK
Market Abuse Regulation or other applicable regulation.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRABMITMTMJBTF



            Copyright 2019 Regulatory News Service, all rights reserved